Life Sciences Industry Leader Brian Kim Joins Summit Partners as Executive-in-Residence

Global growth equity investor Summit Partners today announced the addition of Brian Kim to the firm’s Executive-in-Residence (“EIR”) program. In this role, Mr. Kim will work closely with Summit’s healthcare & life sciences team to identify new investment opportunities and advise growth stage companies in the life sciences sector.

Mr. Kim joins Summit’s EIR program from LGC, an international life sciences tools company. Most recently, Mr. Kim worked at LGC as an Executive Director and President of the Genomics Division, helping lead the company’s successful sale to Cinven, Astorg and ADIA in early 2020. Prior to LGC, Mr. Kim was the President of PerkinElmer’s Life Science and Tools Division, where he managed a global portfolio of products, including instruments, reagents, software and services. Previously, Mr. Kim held a variety of leadership positions at other global life sciences organizations, including Merck Millipore (a division of Merck) and Life Technologies.

“Brian is an experienced life sciences executive with a passion for driving product innovation and a talent for scaling high-growth businesses,” said Ross Stern, a Principal with Summit Partners. “He has substantial experience building and leading companies on a global scale. We are thrilled to bring Brian’s perspective to Summit’s EIR program.”

“Summit has deep experience in and understanding of today’s complex healthcare and life sciences landscape,” said Mr. Kim. “I am thrilled to work alongside the Summit team in this role and I look forward to leveraging the firm’s experience and knowledge to help drive growth in the life sciences industry.”

Mr. Kim holds a BA in history from the University of Pennsylvania, a BSE in business and managerial economics from the Wharton School at the University of Pennsylvania and an MBA from the Tuck School of Business at Dartmouth College.

Summit has been active in the healthcare and life sciences sector for more than three decades. Since the firm’s founding in 1984, Summit has partnered with more than 100 companies across the healthcare services, healthcare IT and life sciences sectors.

Summit’s EIR program is an established element of the firm’s growth-oriented investing strategy. Since its inception, the program has facilitated collaboration between seasoned industry executives and Summit’s investment teams, working to identify sector-specific opportunities in which EIRs may support companies in an ongoing capacity through board or leadership roles.

About Summit Partners

Founded in 1984, Summit Partners is a global alternative investment firm that is currently managing more than $21 billion in capital dedicated to growth equity, fixed income and public equity opportunities. Summit invests across growth sectors of the economy and has invested in more than 500 companies in technology, healthcare, consumer, financial and business services, and other growth industries. Summit maintains offices in North America and Europe and invests in companies around the world. For more Summit stories and to learn more about #TheSummitPartnersNetwork, visit or follow on LinkedIn.

In the United States of America, Summit Partners operates as an SEC-registered investment advisor. In the United Kingdom, this document is issued by Summit Partners LLP, a firm authorized and regulated by the Financial Conduct Authority. Summit Partners LLP is a limited liability partnership registered in England and Wales with registered number OC388179 and its registered office is at 11-12 Hanover Square, London, W1S 1JJ, UK. This document is intended solely to provide information regarding Summit Partners’ potential financing capabilities for prospective portfolio companies.


Meg Devine
+1 617.824.1047

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.